共 192 条
[1]
Lip GY(2017)Stroke prevention in atrial fibrillation: past, present and future Thromb Haemost 117 1230-1239
[2]
Freedman B(2007)Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857-867
[3]
De Caterina R(2018)Antithrombotic therapy for atrial fibrillation: chest guideline and expert panel report Chest 154 1121-1201
[4]
Potpara TS(2018)Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review Thromb Haemost 118 2171-2187
[5]
Hart RG(2010)A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 1093-1100
[6]
Pearce LA(2016)Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores J Thromb Haemost 14 1711-1714
[7]
Aguilar MI(2011)Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study Thromb Haemost 106 739-749
[8]
Lip GYH(2013)The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation J Am Coll Cardiol 62 2199-2204
[9]
Banerjee A(2013)Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial Thromb Haemost 110 1074-1079
[10]
Boriani G(2019)Should we judge stroke risk by static or dynamic risk scores? a focus on the dynamic nature of stroke and bleeding risks in patients with atrial fibrillation J Cardiovasc Pharmacol 74 491-498